1-4 of 4
Félix Jaminion
Close
Sort by
Journal Articles

Pharmacokinetic Characterization and Exposure-Response Relationship of Crovalimab in the COMPOSER and COMMODORE 3 Trials of Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH)

Simon Buatois, Khaled Benkali, Andrea Henrich, Félix Jaminion, Yuchen Zhang, Alexandre Sostelly
Journal: Blood
Blood (2022) 140 (Supplement 1): 2918–2920.
https://doi.org/10.1182/blood-2022-158244
Published: 2022
Journal Articles

Population Pharmacokinetics and Exposure-Response Analyses for Glofitamab in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma (R/R NHL): Confirmation of Efficacy and CRS Mitigation in Patients with Step-up Dosing

Nassim Djebli, Peter N Morcos, Félix Jaminion, Elena Guerini, Nicole A Kratochwil, Nicole Justies, Eginhard Schick, Antonia Kwan, Kathryn Humphrey, Linda Lundberg, David Carlile
Journal: Blood
Blood (2020) 136 (Supplement 1): 1–2.
https://doi.org/10.1182/blood-2020-136311
Published: 2020
Journal Articles

Population Pharmacokinetic/Pharmacodynamic Modelling from the Phase I/II COMPOSER Trial to Predict Lowering of Lactate Dehydrogenase in Crovalimab-Treated Patients with Paroxysmal Nocturnal Hemoglobinuria

Simon Buatois, PharmD, PhD, Alexandre Sostelly, PhD, Antoine Soubret, PhD, Felix Jaminion, Valerie Cosson, PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 9–10.
https://doi.org/10.1182/blood-2020-134590
Published: 2020
Journal Articles

Population Pharmacokinetics and Novel Exposure-Response Analyses to Inform Optimal Biologic Dose Selection for CD20-TCB, a T-Cell-Engaging Bispecific Antibody, in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

Nassim Djebli, PhD PharmD, Felix Jaminion, MSc, Johann Laurent, MSc, Francois Mercier, PhD, Nicole A Kratochwil, PhD, Ann-Marie E Bröske, PhD, Natalie Dimier, PhD, Cristiano Ferlini, MD, Tom Moore, MBChB, Martin Weisser, MD, Peter N Morcos, PharmD
Journal: Blood
Blood (2019) 134 (Supplement_1): 3799.
https://doi.org/10.1182/blood-2019-123712
Published: 2019